Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery

Current Pharmacology Reports

Volumn 2, Issue 1, 2016, Pages

  Wang, Yan ^a   Xie, Ying ^a   Oupický, David ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cancer; CXCR4; Drug delivery; Gene delivery; Metastasis; Nanoparticles; siRNA delivery

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NANOPARTICLE; PHOSPHATIDYLINOSITOL 3 KINASE; PLERIXAFOR; RADIOISOTOPE; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; T 140; VIOLOGEN;

CELL MIGRATION; GENE SILENCING; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 84993941069     PISSN: None     EISSN: 2198641X     Source Type: Journal    
DOI: 10.1007/s40495-015-0044-8     Document Type: Review

References (79)

1. Smith H, Whittall C, Weksler B, Middleton J. Chemokines stimulate bidirectional migration of human mesenchymal stem cells across bone marrow endothelial cells. Stem Cells Dev. 2012;21(3):476–86.
2. Le Y, Zhou Y, Iribarren P, Wang J. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol. 2004;1(2):95–104.
3. Balkwill FR. The chemokine system and cancer. J Pathol. 2012;226(2):148–57.
4. Ganju RK, Brubaker SA, Meyer J, Dutt P, Yang Y, Qin S, et al. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem. 1998;273(36):23169–75.
5. Goldsmith ZG, Dhanasekaran DN. G protein regulation of MAPK networks. Oncogene. 2007;26(22):3122–42.
6. Bendall LJ, Baraz R, Juarez J, Shen W, Bradstock KF. Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia. Cancer Res. 2005;65(8):3290–8.
7. Wang JF, Park IW, Groopman JE. Stromal cell-derived factor-1alpha stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: roles of phosphoinositide-3 kinase and protein kinase C. Blood. 2000;95(8):2505–13.
8. Vlahakis SR, Villasis-Keever A, Gomez T, Vanegas M, Vlahakis N, Paya CV. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J Immunol. 2002;169(10):5546–54.
9. Mellado M, Vila-Coro AJ, Martinez C, Rodriguez-Frade JM. Receptor dimerization: a key step in chemokine signaling. Cell Mol Biol. 2001;47(4):575–82.
10. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49(1):219–30.
11. Ishikawa T, Nakashiro K, Klosek SK, Goda H, Hara S, Uchida D, et al. Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. Oncol Rep. 2009;21(3):707–12.
12. Kubic JD, Lui JW, Little EC, Ludvik AE, Konda S, Salgia R, et al. PAX3 and FOXD3 promote CXCR4 expression in melanoma. J Biol Chem. 2015;290(36):21901–14.
13. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem. 2005;280(23):22473–81.
14. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, et al. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat. 2006;97(3):275–83.
15. Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, et al. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist. 2009;14(12):1182–8.
16. Kato M, Kitayama J, Kazama S, Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res. 2003;5(5):R144–50.
17. Chu QD, Holm NT, Madumere P, Johnson LW, Abreo F, Li BDL. Chemokine receptor CXCR4 overexpression predicts recurrence for hormone receptor-positive, node-negative breast cancer patients. Surgery. 2011;149(2):193–9.
18. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37–40.
19. Fernandis AZ, Prasad A, Band H, Klosel R, Ganju RK. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene. 2004;23(1):157–67.
20. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene. 2005;24(27):4462–71.
21. Luker KE, Luker GD. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2006;238(1):30–41.
22. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, et al. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010;29(4):709–22.
23. Egorova A, Kiselev A, Hakli M, Ruponen M, Baranov V, Urtti A. Chemokine-derived peptides as carriers for gene delivery to CXCR4 expressing cells. J Gene Med. 2009;11(9):772–81.
24. Guo P, You JO, Yang J, Jia D, Moses MA, Auguste DT. Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm. 2014;11(3):755–65.
25. Unzueta U, Cespedes MV, Ferrer-Miralles N, Casanova I, Cedano J, Corchero JL, et al. Intracellular CXCR4(+) cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine. 2012;7:4533–44.
26. Chittasupho C, Lirdprapamongkol K, Kewsuwan P, Sarisuta N. Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles. Eur J Pharm Biopharm. 2014;88(2):529–38.
27. Wang RT, Zhi XY, Yao SY, Zhang Y. LFC131 peptide-conjugated polymeric nanoparticles for the effective delivery of docetaxel in CXCR4 overexpressed lung cancer cells. Colloids Surf B-Biointerfaces. 2015;133:43–50.
28. Snyder EL, Saenz CC, Denicourt C, Meade BR, Cui XS, Kaplan IM, et al. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res. 2005;65(23):10646–50.
29. de la Torre C, Casanova I, Acosta G, Coll C, Moreno MJ, Albericio F, et al. Gated mesoporous silica nanoparticles using a double-role circular peptide for the controlled and target-preferential release of doxorubicin in CXCR4-expressing lymphoma cells. Adv Funct Mater. 2015;25(5):687–95.
30. Egorova A, Bogacheva M, Shubina A, Baranov V, Kiselev A. Development of a receptor-targeted gene delivery system using CXCR4 ligand-conjugated cross-linking peptides. J Gene Med. 2014;16(11–12):336–51.
31. Driessen WH, Fujii N, Tamamura H, Sullivan SM. Development of peptide-targeted lipoplexes to CXCR4-expressing rat glioma cells and rat proliferating endothelial cells. Mol Ther. 2008;16(3):516–24.
32. Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K, et al. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol. 2006;33(4):489–94.
33. Kuil J, Buckle T, Oldenburg J, Yuan H, Borowsky AD, Josephson L, et al. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. Mol Pharm. 2011;8(6):2444–53.
34. Kuil J, Buckle T, Yuan H, van den Berg NS, Oishi S, Fujii N, et al. Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide. Bioconjug Chem. 2011;22(5):859–64.
35. Tarasov SG, Gaponenko V, Howard OM, Chen Y, Oppenheim JJ, Dyba MA, et al. Structural plasticity of a transmembrane peptide allows self-assembly into biologically active nanoparticles. Proc Natl Acad Sci U S A. 2011;108(24):9798–803.
36. Guo P, You JO, Yang J, Moses MA, Auguste DT. Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. Biomaterials. 2012;33(32):8104–10.
37. Nimmagadda S, Pullambhatla M, Pomper MG. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med. 2009;50(7):1124–30.
38. Le Bon B, Van Craynest N, Daoudi JM, Di Giorgio C, Domb AJ, Vierling P. AMD3100 conjugates as components of targeted nonviral gene delivery systems: synthesis and in vitro transfection efficiency of CXCR4-expressing cells. Bioconjug Chem. 2004;15(2):413–23.
39. Misra AC, Luker KE, Durmaz H, Luker GD, Lahann J. CXCR4-targeted nanocarriers for triple negative breast cancers. Biomacromolecules. 2015;16(8):2412–7.
40. Gao DY, Lin Ts T, Sung YC, Liu YC, Chiang WH, Chang CC, et al. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials. 2015;67:194–203.
41. Li J, Oupicky D. Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric plerixafor. Biomaterials. 2014;35(21):5572–9.
42. Li J, Zhu Y, Hazeldine ST, Li C, Oupicky D. Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion. Angew Chem Int Ed Engl. 2012;51(35):8740–3.
43. Wang Y, Li J, Chen Y, Oupicky D. Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes. Biomaterials Sci. 2015;3(7):1114–23.
44. Wang Y, Li J, Oupicky D. Polymeric plerixafor: effect of PEGylation on CXCR4 antagonism, cancer cell invasion, and DNA transfection. Pharm Res. 2014;31(12):3538–48.
45. Wang Y, Hazeldine ST, Li J, Oupicky D. Development of functional poly(amido amine) CXCR4 antagonists with the ability to mobilize leukocytes and deliver nucleic acids. Adv Healthcare Mater. 2015;4(5):729–38.
46. Li J, Lepadatu AM, Zhu Y, Ciobanu M, Wang Y, Asaftei SC, et al. Examination of structure-activity relationship of viologen-based dendrimers as CXCR4 antagonists and gene carriers. Bioconjug Chem. 2014;25(5):907–17.
47. Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla ZM, Pomper MG. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res. 2010;70(10):3935–44.
48. De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med. 2011;52(6):986–93.
49. De Clercq E. The bicyclam AMD3100 story. Nature Rev Drug Discov. 2003;2(7):581–7.
50. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64(23):8604–12.
51. Engl T, Relja B, Marian D, Blumenberg C, Muller I, Beecken WD, et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia. 2006;8(4):290–301.
52. Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013;19(2):357–66.
53. Abedini F, Hosseinkhani H, Ismail M, Domb AJ, Omar AR, Chong PP, et al. Cationized dextran nanoparticle-encapsulated CXCR4-siRNA enhanced correlation between CXCR4 expression and serum alkaline phosphatase in a mouse model of colorectal cancer. Int J Nanomedicine. 2012;7:4159–68.
54. Abedini F, Ismail M, Hosseinkhani H, Ibrahim TA, Omar AR, Chong PP, et al. Effects of CXCR4 siRNA/dextran-spermine nanoparticles on CXCR4 expression and serum LDH levels in a mouse model of colorectal cancer metastasis to the liver. Cancer Manag Res. 2011;3:301–9.
55. Jiang K, Li J, Yin JP, Ma Q, Yan B, Zhang X, et al. Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy. Biomaterials. 2015;59:77–87.
56. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28(2 Suppl 8):29–35.
57. Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47.
58. Romain B, Hachet-Haas M, Rohr S, Brigand C, Galzi JL, Gaub MP, et al. Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. Mol Cancer. 2014;13:58.
59. Lee Y, Chen Y, Tarasova NI, Gaponenko V. The structure of monomeric components of self-assembling CXCR4 antagonists determines the architecture of resulting nanostructures. Nanotechnology. 2011;22(50):505101.
60. Asaftei S, Huskens D, Schols D. HIV-1 X4 activities of polycationic “viologen” based dendrimers by interaction with the chemokine receptor CXCR4: study of structure–activity relationship. J Med Chem. 2012;55(23):10405–13.
61. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.
62. Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology. 2014;59(4):1435–47.
63. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31(17):2205–18. doi:10.1200/JCO.2012.46.3653.
64. Dubrovska A, Hartung A, Bouchez LC, Walker JR, Reddy VA, Cho CY, et al. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer. 2012;107(1):43–52.
65. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A. 1997;94(5):1925–30.
66. Federsppiel B, Melhado IG, Duncan AM, Delaney A, Schappert K, Clark-Lewis I, et al. Molecular cloning of the cDNA and chromosomal localization of the gene for a putative seven-transmembrane segment (7-TMS) receptor isolated from human spleen. Genomics. 1993;16(3):707–12.
67. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjo T. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science. 1993;261(5121):600–3.
68. Bhattacharyya S, Khan JA, Curran GL, Robertson JD, Bhattacharya R, Mukherjee P. Efficient delivery of gold nanoparticles by dual receptor targeting. Adv Mater. 2011;23(43):5034–8.
69. Chen C, Hu H, Qiao M, Zhao X, Wang Y, Chen K, et al. Anti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrier. J Drug Target. 2015;23(4):311–22.
70. Meng S, Su B, Li W, Ding Y, Tang L, Zhou W, et al. Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes. Nanotechnology. 2010;21(41):415103–9.
71. Ringhieri P, Diaferia C, Galdiero S, Palumbo R, Morelli G, Accardo A. Liposomal doxorubicin doubly functionalized with CCK8 and R8 peptide sequences for selective intracellular drug delivery. J Pept Sci. 2015;21(5):415–25.
72. Saul JM, Annapragada AV, Bellamkonda RV. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release. 2006;114(3):277–87.
73. Schubert I, Stein C, Fey GH. Dual-targeting for the elimination of cancer cells with increased selectivity. Antibodies. 2012;1(3):2–18.
74. Sewell SL, Giorgio TD. Synthesis and enzymatic cleavage of dual-ligand quantum dots. Mater Sci Eng C. 2009;29(4):1428–32.
75. Yang Z, Tang W, Luo X, Zhang X, Zhang C, Li H, et al. Dual-ligand modified polymer-lipid hybrid nanoparticles for docetaxel targeting delivery to Her2/neu overexpressed human breast cancer cells. J Biomed Nanotechnol. 2015;11(8):1401–17.
76. Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, et al. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012;7(4):e34038.
77. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, et al. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol. 1998;72(8):6381–8.
78. Trent JO, Wang ZX, Murray JL, Shao W, Tamamura H, Fujii N, et al. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem. 2003;278(47):47136–44.
79. Zhang WB, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, Omagari A, et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem. 2002;277(27):24515–21.